Brain metastases in clinical trial participants with KRAS-mutated advanced non-small cell lung cancer receiving docetaxel: Pooled data analysis

Lung, Respiratory and Thoracic Cancer

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer

Oncologist

Skoulidis F, Li BT, Hochmair M, Govindan R, Vincent M, van der Wekken AJ, Reguart Aransay N, O'Byrne KJ, Girard N, Griesinger F, Nishio M, Häfliger S, Lindsay C, Reinmuth N, Paulus A, Papakotoulas P, Kim SW, Ferreira CG, Pasello G, Duruisseaux M, Gennatas S, Dimou A, Mehta B, Kormany W, Nduka C, Sylvester BE, Ardito-Abraham C, Wang Y, de Langen AJ

doi: 10.1093/oncolo/oyae356

Lung, Respiratory and Thoracic Cancer

Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials

J Clin Oncol

Sikkema BJ, Baart SJ, Paats MS, Smit EF, Schols AMWJ, Mathijssen RHJ, van Rossum EFC, Dingemans AC

doi: 10.1200/JCO-24-01579

Lung, Respiratory and Thoracic Cancer

Clinical utility of circulating tumor DNA in patients with advanced KRAS(G12C)-mutated non-small cell lung cancer treated with sotorasib

J Thorac Oncol

Ernst SM, van Marion R, Atmodimedjo PN, de Jonge E, Mathijssen RHJ, Paats MS, de Bruijn P, Koolen SL, von der Thüsen JH, Aerts JGJV, van Schaik RHN, Dubbink HJ, Dingemans AC

doi: 10.1016/j.jtho.2024.04.007

Lung, Respiratory and Thoracic Cancer

Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials

Lung Cancer

Auclin E, Roulleaux Dugage M, Gorria T, Vauchier C, Thibault C, Laguna JC, Lupinacci L, Crous C, Naigeon M, Oudard S, Besse B, Mezquita L

doi: 10.1016/j.lungcan.2024.108039

Lung, Respiratory and Thoracic Cancer

Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Seconday Analysis of a Randomized Clinical Trial

JAMA Oncol

Altorki N, Wang X, Damman B, Jones DR, Wigle D, Port J, Conti M, Ashrafi AS, Lieberman M, Landreneau R, Yasufuku K, Yang S, Mitchell JD, Keenan R, Bauer T, Miller D, Kozono D, Mentlick J, Vokes E, Stinchcombe TE

doi: 10.1001/jamaoncol.2024.2491

Lung, Respiratory and Thoracic Cancer

Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3

J Thorac Oncol

Gray JE, Markovets A, Reungwetwattana T, Majem M, Nogami N, Peled N, Lee JS, Cho BC, Chewaskulyong B, John T, Han JY, Sebastian M, Todd A, Rukazenkov Y, Barrett C, Chmielecki J, Lee SM, Ramalingam SS, Hartmaier R

doi: 10.1016/j.jtho.2024.07.008

Lung, Respiratory and Thoracic Cancer

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

Eur J Cancer

Mark M, Froesch P, Gysel K, Rothschild SI, Addeo A, Ackermann CJ, Chiquet S, Schneider M, Ribi K, Maranta AF, Bastian S, von Moos R, Joerger M, Früh M, Swiss Group for Clinical Cancer Research (SAKK)

doi: 10.1016/j.ejca.2024.113600

Lung, Respiratory and Thoracic Cancer

Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany

Eur J Cancer

Stratmann JA, Althoff FC, Doebel P, Rauh J, Trummer A, Hünerlitürkoglu AN, Frost N, Yildirim H, Christopoulos P, Burkhard O, Büschenfelde CMZ, Becker von Rose A, Alt J, Aries SP, Webendörfer M, Kaldune S, Uhlenbruch M, Tritchkova G, Waller CF, Rittmeyer A, Hoffknecht P, Braess J, Kopp HG, Grohé C, Schäfer M, Schumann C, Griesinger F, Kuon J, Sebastian M, Reinmuth N

doi: 10.1016/j.ejca.2024.113911

Lung, Respiratory and Thoracic Cancer

The IASLC Lung Cancer Staging Project: Recommendation to Introduce Spread Through Air Spaces (STAS) as a Histologic Descriptor in the 9(th) Edition of the TNM Classification of Lung Cancer.Analysis of 4,061 Pathologic Stage I Non-Small cell Lung Carcinomas

J Thorac Oncol

Travis WD, Eisele M, Nishimura KK, Aly R, Bertoglio P, Chou TY, Detterbeck FC, Donnington J, Fang W, Joubert P, Kernstine K, Kim YT, Lievens Y, Liu H, Lyons G, Mino-Kenudson M, Nicholson AG, Papotti M, Rami-Porta R, Rusch V, Sakai S, Ugalde P, Van Schil P, Yang J, Cilento VJ, Yotsukura M, Asamura H, Members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Members of the Advisory Boards, and Participating Institutions of the Lung Cancer Domain

doi: 10.1016/j.jtho.2024.03.015

Related content

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer

Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials

Clinical utility of circulating tumor DNA in patients with advanced KRAS(G12C)-mutated non-small cell lung cancer treated with sotorasib

Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials

Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Seconday Analysis of a Randomized Clinical Trial

Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany

The IASLC Lung Cancer Staging Project: Recommendation to Introduce Spread Through Air Spaces (STAS) as a Histologic Descriptor in the 9(th) Edition of the TNM Classification of Lung Cancer.Analysis of 4,061 Pathologic Stage I Non-Small cell Lung Carcinomas